SO-32 Biomarker analysis of the phase III IMblaze370 trial of atezolizumab plus cobimetinib or atezolizumab monotherapy vs regorafenib in third-line CRC
| Autor: | Argiles, G., Bendell, J., Kim, T., Wongchenko, M., DuPree, K., Mahrus, S., Qu, X., Shi, Y., Uyei, A., Roberts, L., Yan, Y., Ciardiello, F. |
|---|---|
| Zdroj: | In Annals of Oncology July 2020 31 Supplement 3:S229-S229 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|